RYBREVANT® (amivantamab-vmjw) with standard care now approved in the U.S. as the sole targeted treatment reducing disease progression risk by over 50% for second-line EGFR-mutated advanced lung cancer.

Sep 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Edgewise Therapeutics Reports Favorable Results from Phase 1 Study in Healthy Volunteers and Phase 2 CIRRUS-HCM Study in Obstructive Hypertrophic Cardiomyopathy Patients.

4DMT Showcases Strong and Lasting Clinical Outcomes for 4D-150 and Unveils 4FRONT Phase 3 Program Plan at 4D-150 Wet AMD Development Event.

Transcenta Shares Promising Results from First-Line Triple Combination Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024.

Genentech revealed favorable topline results from the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).

Summary of Key R&D Progress in Global Innovative Drugs from September 16 to September 22.

On September 19, 2024, the NMPA accepted Hengrui Pharmaceutical's marketing authorization application for the Class 1 new drug Retlirafusp-α Injection (SHR-1701).

Summary of Global Pharmaceutical Licensing Agreements and Financing Events from September 16 to September 22.

RNA Interference (RNAi) is a gene-silencing mechanism first discovered in Caenorhabditis elegans, triggered by double-stranded small interfering RNA (siRNA).

Sep 20th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The development and application of siRNA drugs mark a revolution in the field of gene therapy, as they cleverly utilize the cellular RNA interference (RNAi) pathway to achieve precise regulation of disease-related gene expression.